<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000500005</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i5.2059</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prevalencia de eosinofilia y características clínicas en una cohorte de pacientes con enfermedad pulmonar obstructiva crónica en un hospital de tercer nivel de Puebla]]></article-title>
<article-title xml:lang="en"><![CDATA[Eosinophilia prevalence and clinical characteristics in a cohort of patients with chronic obstructive pulmonary disease in a third-level hospital in Puebla.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera-García]]></surname>
<given-names><![CDATA[José Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montiel Castro]]></surname>
<given-names><![CDATA[José Sabino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caballero-López]]></surname>
<given-names><![CDATA[Christopherson Gengyny]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arellano-Montellano]]></surname>
<given-names><![CDATA[Ek Ixel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jaramillo-Arellano]]></surname>
<given-names><![CDATA[Luis Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinosa Arellano]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario de Puebla  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario de Puebla  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario de Puebla  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Benemérita Universidad Autónoma del Estado de Puebla Departamento de Pregrado ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>5</numero>
<fpage>692</fpage>
<lpage>696</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000500005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000500005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000500005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  ANTECEDENTES La prevalencia de eosinofilia en la enfermedad pulmonar obstructiva crónica (EPOC) es de gran importancia para la prevención de complicaciones y tratar episodios de sobreagudización. La existencia de un biomarcador permitiría este seguimiento. La revisión de la bibliografía pone de manifiesto la posible relación eosinofilia-enfermedad pulmonar obstructiva crónica. Se tiene poca información en estudios médicos.  MATERIAL Y MÉTODO  Estudio descriptivo y observacional de la población atendida en la consulta externa de Neumología en el Hospital Universitario de Puebla. Se analizaron las siguientes variables: edad, sexo, años de diagnóstico de enfermedad pulmonar obstructiva crónica, hemograma (se estableció el diagnóstico de eosinofilia con &gt; 2% o más de 200 células totales), gravedad (por GOLD) y número de exacerbaciones en un año de estudio.  RESULTADOS Se incluyeron 50 pacientes con diagnóstico de enfermedad pulmonar obstructiva crónica (74% mujeres y 26% hombres), 50% asociado con tabaquismo y 50% asociado con humo de leña; 36% tenían eosinofilia representativa (mayor de 2% o mayor de 200 células totales), 64% tenían eosinofilia no representativa (menos de 2% o menos de 200 células totales).  CONCLUSIÓN Este trabajo demuestra en una población la importancia de la eosinofilia como biomarcador en el fenotipo de la enfermedad pulmonar obstructiva crónica que permita el tratamiento adecuado y dirigido a mejorar la calidad de vida y a disminuir la progresión y aparición de complicaciones y exacerbaciones.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  OBJECTIVE The prevalence of eosinophilia in chronic obstructive pulmonary disease is of great importance for the prevention of complications and to treat episodes of overactivity. The existence of a bio-marker would allow this monitoring. The review of the literature reveals the possible eosinophilia-chronic obstructive pulmonary disease relationship. There is little information in medical studies.  MATERIAL AND METHOD  We designed a descriptive observational study of the population attended in the external consultation of Pneumology in the University Hospital of Puebla. The following variables were analyzed: age, sex, years of diagnosis of chronic obstructive pulmonary disease, blood count (diagnosis of eosinophilia with &gt; 2% or more than 200 total cells), severity (by GOLD) and number of exacerbations in one year of study.  RESULTS Fifty patients with a diagnosis of chronic obstructive pulmonary disease (74% female and 26% male), 50% associated with smoking and 50% associated with wood smoke were present; 36% had representative eosinophilia (greater than 2% or greater than 200 total cells), 64% had non-representative eosinophilia (less than 2% or less than 200 total cells).  CONCLUSION This work demonstrates in a population the importance of eosinophilia as a biomarker in the phenotype of chronic obstructive pulmonary disease that allows adequate treatment and aimed at improving quality of life and to decrease the progression and appearance of complications and exacerbations.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Eosinofilia]]></kwd>
<kwd lng="es"><![CDATA[enfermedad pulmonar obstructiva crónica]]></kwd>
<kwd lng="es"><![CDATA[biomarcador]]></kwd>
<kwd lng="en"><![CDATA[Eosinophilia]]></kwd>
<kwd lng="en"><![CDATA[Chronic obstructive pulmonary disease]]></kwd>
<kwd lng="en"><![CDATA[Biomarker]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[Dave]]></given-names>
</name>
</person-group>
<source><![CDATA[on behalf of the ECLIPSE investigators: Blood eosinophil measurements may be useful for selecting COPD patients for different therapeutic approaches]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>Grupo de Trabajo de GesEPOC</collab>
<article-title xml:lang=""><![CDATA[Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Espanola de la EPOC (GesEPOC)]]></article-title>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2012</year>
<volume>48</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>2-58</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hurst]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Susceptibility to exacerbation in chronic obstructive pulmonary disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>363</volume>
<page-range>1128-38</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Postma]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The asthma-COPD overlap syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<page-range>1241-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soler-Cataluna]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus document on the overlap phenotype COPD-asthma in COPD]]></article-title>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2012</year>
<volume>48</volume>
<page-range>331-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eosinophilic inflammation in COPD prevalence and clinical characteristics]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2014</year>
<volume>44</volume>
<page-range>1697-700</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christenson]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asthma-COPD overlap Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2015</year>
<volume>191</volume>
<page-range>758-66</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pascoe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease A secondary analysis of date fromtwo parallel randomised controlled trials]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2015</year>
<volume>3</volume>
<page-range>435-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddiqui]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood eosinophils A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2015</year>
<volume>192</volume>
<page-range>523-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marks-Konczalik]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with = 2% and &amp;gt; 2% blood eosinophils]]></article-title>
<source><![CDATA[Respir Med]]></source>
<year>2015</year>
<volume>109</volume>
<page-range>860-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>12</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siva]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<collab>et al airway inflammation and exacerbations of COPD: A randomised controlled trial</collab>
<source><![CDATA[Eur Respir]]></source>
<year>2007</year>
<volume>29</volume>
<page-range>906-13</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
